Abstract: The invention disclosed herein is for an in vitro cell-based assay for predicting the conversion from mild cognitive impairment to Alzheimer's disease in a patient who has received a diagnosis of MCI. The method comprises the following steps: a) culturing human hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of proliferation of said progenitor cells; b) subsequently culturing said hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of differentiation of said progenitor cells; c) determining the level of proliferation of said cultured progenitor cells; d) determining the average cell count of said cultured progenitor cells; and e) monitoring apoptotic cell death after differentiation of the proliferated hippocampal progenitor cells, wherein the outcomes of each of (c) to (e) are applied to a statistical analysis, the result of which is predictive of conversion from MCI to AD in the patient.

Abstract: The invention disclosed herein is for an in vitro cell-based assay for predicting the conversion from mild cognitive impairment to Alzheimer's disease in a patient who has received a diagnosis of MCI. The method comprises the following steps: a) culturing human hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of proliferation of said progenitor cells; b) subsequently culturing said hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of differentiation of said progenitor cells; c) determining the level of proliferation of said cultured progenitor cells; d) determining the average cell count of said cultured progenitor cells; and e) monitoring apoptotic cell death after differentiation of the proliferated hippocampal progenitor cells, wherein the outcomes of each of (c) to (e) are applied to a statistical analysis, the result of which is predictive of conversion from MCI to AD in the patient.

Abstract: The present invention provides an isolated cell obtainable from the CTX0E03 neural stem cell line for use in the treatment of a disorder associated with elevated levels of pro-inflammatory cytokines, wherein the disorder is selected from unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, autism and autistic syndrome disorders.

Abstract: The present invention provides an isolated cell obtainable from the CTX0E03 neural stem cell line for use in the treatment of a disorder associated with elevated levels of pro-inflammatory cytokines, wherein the disorder is selected from unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, autism and autistic syndrome disorders.

Abstract: Provided is a gasket for a fuel pump unit configured with a second outlet port for accommodating a pressure sensor to monitor the downstream pressure of pumped fuel. The gasket is adapted for placement between a pump cover incorporating the second outlet port and a pump body containing a gear pump. Providing fluid communication between a first outlet port downstream of the gear pump and the second outlet port is a passageway disposed through the pump cover and pump body. To avoid obstructing the passageway, the gasket includes an aperture. To prevent high pressure fuel from being forced through the gasket and leaked from the pump unit, the gasket includes a leakage collection channel having a first leg, a second leg and an intermediate portion surrounding the aperture. The leakage collection channel is adapted to return leaked fuel to a low pressure reservoir between the pump cover and pump body.

Abstract: This invention relates to diagnostics in the fields of neurotoxicology and neuropathology and more particularly to the visualisation of areas of damage to nerve tissue. In particular, the present invention relates to the use SCIP as a marker of neurological damage.

Abstract: Pluripotent cells that are suitable for transplantation therapy, to repair neural damage, are identified, e.g. by differential display, from a gene expression profile for a selected cell, which can be compared with that obtained from a control cell.

Abstract: Pluripotent cells that are suitable for transplantation therapy, to repair neural damage, are identified, e.g. by differential display, from a gene expression profile for a selected cell, which can be compared with that obtained from a control cell.